Nintedanib in patients with progressive fibrosing interstitial lung diseases – subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial - Wells, A U; Flaherty, K R; Brown, K K (Lancet Resp Med, 2020)
et al.